基于来自MIMIC-IV数据库的医学诊断数据,探索高血压患者心力衰竭进展的预测因素
Jinmyung Jung1, Doyoon Kim1, Inkyung Hwang1
1Division of Data Science, College of Information and Communication Technology, The University of Suwon, Hwaseong 18323, Republic of Korea.
Bioengineering (Basel, Switzerland)
|June 27, 2024
概括
在高血压患者中确定心力衰竭风险因素是关键. 这项研究发现了21个关键预测因素,包括心房动和功能衰竭,以帮助早期干预.
科学领域:
- 心脏病学 心脏病学
- 医疗信息学 医疗信息学
- 公共卫生 公共卫生
背景情况:
- 心力衰竭显著增加死亡率,特别是在高血压患者中.
- 早期识别高血压中心力衰竭进展因素对于及时干预至关重要.
- 使用高血压前诊断史的辅助工具来预测高血压诊断时心力衰竭的发生.
研究的目的:
- 确定高血压患者心力衰竭进展的预测因素.
- 用不同的年龄组分析特定年龄的预测因素.
- 为改善高血压患者的风险评估提供见解.
主要方法:
- 利用MIMIC-IV数据库查看高血压患者的医学诊断记录.
- 采用了千平方测试和XGBoost模型来识别因子.
- 分析了四个年龄组的特定预测因素:所有年龄,0-65,65-80岁和80岁以上.
主要成果:
- 奇平方测试确定了每个年龄组的不同因素数量 (所有年龄组为34,随着年龄的增长而下降).
- XGBoost模型显示,随着年龄的增长,因素的数量越来越多 (所有年龄段的19个,80岁以上的高达33个).
- 总的来说,确定了21个预测因素,包括心房动,抗凝剂使用,功能衰竭,阻塞性肺病和贫血.
结论:
- 该研究确定了高血压患者心力衰竭的关键预测因素.
- 调查结果强调了在风险评估中考虑特定的并发病和治疗的重要性.
- 鉴定的因素可以为高血压中主动心力衰竭管理的临床实践提供信息.
更多相关视频
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.3K
07:13A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
6.4K
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:22Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564